These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30798695)

  • 1. HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial.
    Claassen CW; Keckich D; Nwizu C; Abimiku A; Salami D; Obiefune M; Gilliam BL; Amoroso A
    J Int Assoc Provid AIDS Care; 2019; 18():2325958218823209. PubMed ID: 30798695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ritonavir-boosted lopinavir as maintenance monotherapy in HIV-infected patients who achieved viral suppression during a second-line protease inhibitor-based regimen: a pilot randomized trial (BIDI-MONO).
    Siripassorn K; Chottanapund S; Prasithsirikul W; Manosuthi W
    J Int Assoc Provid AIDS Care; 2014; 13(4):353-60. PubMed ID: 25513033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
    PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
    Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).
    Nunes EP; Santini de Oliveira M; Merçon M; Zajdenverg R; Faulhaber JC; Pilotto JH; Ribeiro JE; Norton M; Schechter M
    HIV Clin Trials; 2009; 10(6):368-74. PubMed ID: 20133267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
    Delaugerre C; Flandre P; Chaix ML; Ghosn J; Raffi F; Dellamonica P; Jaeger H; Shürmann D; Cohen-Codar I; Van PN; Norton M; Taburet AM; Delfraissy JF; Rouzioux C;
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2934-9. PubMed ID: 19451297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
    Gianotti N; Cozzi-Lepri A; Antinori A; Castagna A; De Luca A; Celesia BM; Galli M; Mussini C; Pinnetti C; Spagnuolo V; d'Arminio Monforte A; Ceccherini-Silberstein F; Andreoni M;
    PLoS One; 2017; 12(2):e0171611. PubMed ID: 28192453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ritonavir-boosted lopinavir as maintenance monotherapy in HIV-infected patients who achieved viral suppression during a second-line protease inhibitor-based regimen: a pilot randomized trial (BIDI-MONO).
    Siripassorn K; Chottanapund S; Prasithsirikul W; Manosuthi W
    J Int Assoc Provid AIDS Care; 2014; 13(4):353-60. PubMed ID: 24378514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.
    Kumarasamy N; Aga E; Ribaudo HJ; Wallis CL; Katzenstein DA; Stevens WS; Norton MR; Klingman KL; Hosseinipour MC; Crump JA; Supparatpinyo K; Badal-Faesen S; Bartlett JA
    Clin Infect Dis; 2015 May; 60(10):1552-8. PubMed ID: 25694653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
    Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
    PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy.
    Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M; Norton M
    HIV Clin Trials; 2006; 7(5):237-45. PubMed ID: 17162317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone.
    McKinnon JE; Arribas JR; Pulido F; Delgado R; Mellors JW
    AIDS; 2006 Nov; 20(18):2331-5. PubMed ID: 17117019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
    Bartlett JA; Ribaudo HJ; Wallis CL; Aga E; Katzenstein DA; Stevens WS; Norton MR; Klingman KL; Hosseinipour MC; Crump JA; Supparatpinyo K; Badal-Faesen S; Kallungal BA; Kumarasamy N
    AIDS; 2012 Jul; 26(11):1345-54. PubMed ID: 22441252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
    Bunupuradah T; Chetchotisakd P; Jirajariyavej S; Valcour V; Bowonwattanuwong C; Munsakul W; Klinbuayaem V; Prasithsirikul W; Sophonphan J; Mahanontharit A; Hirschel B; Bhakeecheep S; Ruxrungtham K; Ananworanich J;
    J Neurovirol; 2012 Dec; 18(6):479-87. PubMed ID: 22993101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.